Probi Past Earnings Performance
Past criteria checks 2/6
Probi has been growing earnings at an average annual rate of 3.7%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 3% per year. Probi's return on equity is 5.7%, and it has net margins of 12%.
Key information
3.7%
Earnings growth rate
3.1%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | 3.0% |
| Return on equity | 5.7% |
| Net Margin | 12.0% |
| Next Earnings Update | 21 Oct 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Probi makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 658 | 79 | 155 | 38 |
| 31 Mar 22 | 642 | 75 | 147 | 37 |
| 31 Dec 21 | 658 | 83 | 143 | 37 |
| 30 Sep 21 | 673 | 79 | 140 | 39 |
| 30 Jun 21 | 709 | 93 | 144 | 37 |
| 31 Mar 21 | 731 | 105 | 144 | 37 |
| 31 Dec 20 | 717 | 93 | 150 | 36 |
| 30 Sep 20 | 699 | 97 | 149 | 33 |
| 30 Jun 20 | 645 | 85 | 144 | 32 |
| 31 Mar 20 | 646 | 88 | 153 | 33 |
| 31 Dec 19 | 626 | 86 | 151 | 31 |
| 30 Sep 19 | 623 | 84 | 154 | 30 |
| 30 Jun 19 | 650 | 90 | 157 | 31 |
| 31 Mar 19 | 623 | 81 | 150 | 31 |
| 31 Dec 18 | 604 | 76 | 147 | 33 |
| 30 Sep 18 | 561 | 53 | 139 | 35 |
| 30 Jun 18 | 525 | 34 | 139 | 34 |
| 31 Mar 18 | 544 | 29 | 139 | 35 |
| 31 Dec 17 | 612 | 69 | 138 | 37 |
| 30 Sep 17 | 687 | 98 | 147 | 41 |
| 30 Jun 17 | 643 | 117 | 138 | 41 |
| 31 Mar 17 | 544 | 118 | 122 | 40 |
| 31 Dec 16 | 443 | 102 | 103 | 37 |
| 30 Sep 16 | 286 | 74 | 53 | 54 |
| 30 Jun 16 | 248 | 60 | 49 | 48 |
| 31 Mar 16 | 234 | 54 | 53 | 38 |
| 31 Dec 15 | 216 | 49 | 57 | 31 |
| 30 Sep 15 | 220 | 52 | 82 | 0 |
Quality Earnings: PROBS has high quality earnings.
Growing Profit Margin: PROBS's current net profit margins (12%) are lower than last year (13.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PROBS's earnings have grown by 3.7% per year over the past 5 years.
Accelerating Growth: PROBS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: PROBS had negative earnings growth (-15.8%) over the past year, making it difficult to compare to the Biotechs industry average (-26.8%).
Return on Equity
High ROE: PROBS's Return on Equity (5.7%) is considered low.